MX2017002967A - Composicion farmaceutica novedosa que contiene derivado de acido hidroxamico o sal del mismo. - Google Patents

Composicion farmaceutica novedosa que contiene derivado de acido hidroxamico o sal del mismo.

Info

Publication number
MX2017002967A
MX2017002967A MX2017002967A MX2017002967A MX2017002967A MX 2017002967 A MX2017002967 A MX 2017002967A MX 2017002967 A MX2017002967 A MX 2017002967A MX 2017002967 A MX2017002967 A MX 2017002967A MX 2017002967 A MX2017002967 A MX 2017002967A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
acid derivative
hydroxamic acid
salt
composition containing
Prior art date
Application number
MX2017002967A
Other languages
English (en)
Inventor
Honda Tatsuya
Suzumura Yuko
Kato Tomoya
Koseki Yu
Ono Kohei
Original Assignee
Toyama Chemical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toyama Chemical Co Ltd filed Critical Toyama Chemical Co Ltd
Publication of MX2017002967A publication Critical patent/MX2017002967A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Esta composición farmacéutica contiene un derivado de ácido hidroxámico, o una sal del mismo, y un solubilizante, el derivado de ácido hidroxámico es seleccionado de (2S)-2-((4-((4-((1S)-1,2-d ihidroxietil)fenil)etinil)benzoil) (metil)amino)-N-hidroxi-N´-2-di metilmalonamida, (2S)-2-((4-((4-((1R)-1,2-dihidroxietil)fenil)etin il)benzoil) (metil)amino)-N-hidroxi-N´-2-dimetilmaqlonamida y (2S)-N-hidroxi-2-((4-((4-(1S)-1-hidroxi-2-metoxietil)fenil)etinil )benzoil) (metil)amino)-N´,2-dimetilmalonamida. La composición farmacéutica demuestra una fuerte actividad antibacteriana, tiene excelente solubilidad en agua y es útil como fármaco.
MX2017002967A 2014-09-12 2015-09-11 Composicion farmaceutica novedosa que contiene derivado de acido hidroxamico o sal del mismo. MX2017002967A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2014186570 2014-09-12
JP2015108356 2015-05-28
PCT/JP2015/075779 WO2016039433A1 (ja) 2014-09-12 2015-09-11 新規なヒドロキサム酸誘導体またはその塩を含有する医薬組成物

Publications (1)

Publication Number Publication Date
MX2017002967A true MX2017002967A (es) 2017-05-30

Family

ID=55459177

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017002967A MX2017002967A (es) 2014-09-12 2015-09-11 Composicion farmaceutica novedosa que contiene derivado de acido hidroxamico o sal del mismo.

Country Status (14)

Country Link
US (2) US10149911B2 (es)
EP (1) EP3192503B1 (es)
JP (1) JPWO2016039433A1 (es)
KR (1) KR20170048546A (es)
CN (1) CN106794160A (es)
AU (1) AU2015316401A1 (es)
BR (1) BR112017004798A2 (es)
CA (1) CA2960949A1 (es)
IL (1) IL250882A0 (es)
MX (1) MX2017002967A (es)
RU (1) RU2017112319A (es)
SG (1) SG11201701956TA (es)
TW (1) TW201613568A (es)
WO (1) WO2016039433A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017170884A1 (ja) * 2016-03-31 2017-10-05 富山化学工業株式会社 新規なヒドロキサム酸誘導体の製造方法およびその中間体
EP3438088A4 (en) * 2016-03-31 2019-04-17 FUJIFILM Toyama Chemical Co., Ltd. CRYSTALS OF A NEW HYDROXAMIC ACID DERIVATIVE, PROCESS FOR PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITION
WO2018143162A1 (ja) 2017-01-31 2018-08-09 富山化学工業株式会社 ヒドロキサム酸のプロドラッグである化合物またはその塩、凍結乾燥製剤、ＬｐｘＣ阻害剤および抗菌剤
US10085999B1 (en) 2017-05-10 2018-10-02 Arixa Pharmaceuticals, Inc. Beta-lactamase inhibitors and uses thereof
KR102455390B1 (ko) 2017-10-02 2022-10-17 아릭사 파마슈티컬스 인코포레이티드 아즈트레오남 유도체 및 이의 용도
CA3114618C (en) 2018-10-01 2023-09-05 Arixa Pharmaceuticals, Inc. Derivatives of relebactam and uses thereof
CN113614084A (zh) 2019-03-12 2021-11-05 阿里萨制药公司 阿维巴坦衍生物的晶型
US11565999B2 (en) 2019-04-25 2023-01-31 Arixa Pharmaceuticals, Inc. Methods of synthesizing aztreonam derivatives
US20210315902A1 (en) * 2020-03-25 2021-10-14 Forge Therapeutics, Inc. Lpxc inhibitor, formulations, and uses thereof
WO2021195260A1 (en) 2020-03-25 2021-09-30 Forge Therapeutics, Inc. Lpxc inhibitor and methods of making
CN114558004B (zh) * 2022-03-29 2023-08-11 奎马特里克斯有限公司 Qtx125药物制剂

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004062601A2 (en) 2003-01-08 2004-07-29 Chiron Corporation Antibacterial agents
EP1963262A2 (en) 2005-12-15 2008-09-03 Vicuron Pharmaceuticals, Inc. N-hydroxyamide derivatives possessing antibacterial activity
RU2009102275A (ru) 2006-06-26 2010-08-10 Новартис АГ (CH) Органические соединения
JP5227304B2 (ja) * 2007-02-28 2013-07-03 大正製薬株式会社 新規なヒドロキサム酸誘導体
EP2170814B1 (en) 2007-06-12 2016-08-17 Achaogen, Inc. Antibacterial agents
WO2010017060A1 (en) 2008-08-04 2010-02-11 Schering Corporation Urea derivatives as antibacterial agents
JP5455913B2 (ja) 2008-08-27 2014-03-26 大正製薬株式会社 ナフチリジン−ｎ−オキシドを有する新規ヒドロキサム酸誘導体
US8372885B2 (en) 2008-09-17 2013-02-12 Novartis Ag Organic compounds and their uses
CA2735929C (en) 2008-09-19 2013-12-17 Pfizer Inc. Hydroxamic acid derivatives useful as antibacterial agents
KR101826371B1 (ko) * 2010-04-20 2018-02-06 다이쇼 세이야꾸 가부시끼가이샤 신규 히드록삼산 유도체
EP2847168A1 (en) 2012-05-10 2015-03-18 Achaogen, Inc. Antibacterial agents
PT2975022T (pt) * 2013-03-15 2019-06-11 Fujifilm Toyama Chemical Co Ltd Novo derivado de ácido hidroxâmico ou um seu sal
JPWO2015056799A1 (ja) * 2013-10-18 2017-03-09 大正製薬株式会社 ヒドロキサム酸誘導体
JP2016210683A (ja) * 2013-10-18 2016-12-15 大正製薬株式会社 ヒドロキサム酸誘導体

Also Published As

Publication number Publication date
US10149911B2 (en) 2018-12-11
EP3192503A4 (en) 2018-04-18
RU2017112319A3 (es) 2019-04-11
EP3192503A1 (en) 2017-07-19
AU2015316401A1 (en) 2017-04-06
RU2017112319A (ru) 2018-10-12
IL250882A0 (en) 2017-04-30
WO2016039433A1 (ja) 2016-03-17
US20170290918A1 (en) 2017-10-12
CA2960949A1 (en) 2016-03-17
KR20170048546A (ko) 2017-05-08
JPWO2016039433A1 (ja) 2017-06-22
EP3192503B1 (en) 2019-08-14
CN106794160A (zh) 2017-05-31
US20190054179A1 (en) 2019-02-21
TW201613568A (en) 2016-04-16
SG11201701956TA (en) 2017-04-27
BR112017004798A2 (pt) 2017-12-12

Similar Documents

Publication Publication Date Title
MX2017002967A (es) Composicion farmaceutica novedosa que contiene derivado de acido hidroxamico o sal del mismo.
PH12016501813A1 (en) 1,3-benzodioxole derivative
CY1124848T1 (el) Φαρμακευτικες συνθεσεις που περιλαμβανουν azd9291
GEP20186892B (en) 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease
DK3331864T3 (da) 1,3,4-Oxadiazolderivat-forbindelser som histon-deacetylase-6-hæmmer, og den farmaceutiske sammensætning omfattende disse
MX2016016666A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
GEP20186887B (en) Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors
MX2016016593A (es) Nuevos derivados de aminoalquibenzotiazepina y usos de los mismos.
AR103680A1 (es) Inhibidores selectivos de bace1
CL2015000578A1 (es) Compuesto n-(2-(6-fluoro-1-h-indol-3-il)etil)-3-(2,2,3,3-tetrafluoropropoxi)bencilamina o su sal, antagonista del receptor 5-ht6; composicion farmaceutica; uso en el tratamiento de la enfermedad de alzheimer.
CL2016001918A1 (es) Heteroaril amidas como inhibidores de agregación de proteína
MX2018009459A (es) Derivado de sulfonamida y composicion farmaceutica que contiene el mismo.
MX2016011105A (es) Inhibidores de monoacilglicerol aciltransferasa 2 (mgat2) de dihidropiridinona para usarse en el tratamiento de trastornos metabolicos.
MX2017003011A (es) Metodo para usar derivado de acido hidroxamico novedoso y sustancia antibacterial en combinacion.
CL2014001861A1 (es) Compuestos derivados de bencil sulfonamida, inhibidores de mogat-2; compuesto cristalino; composicion farmaceutica; y su uso en el tratamiento de la hipertrigliceridemia.
WO2016057658A8 (en) Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
NZ731607A (en) Dihydropyrimidin-2- one compounds and medical use thereof
EA201692298A1 (ru) Производные карбоксамидов
PH12018501709A1 (en) Naphthridinedione derivatives
EA201691741A1 (ru) Фармацевтическая композиция
WO2016057660A8 (en) Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
WO2016020408A3 (en) Compounds for preventing ototoxicity
EA201690908A1 (ru) Пиразолопиримидиновые соединения
MX2016013684A (es) Composicion farmaceutica que contiene derivado de hidantoina.